Immmunomedics Taps MedCo Veteran Loretta Itri as Chief Medical Officer

Immunomedics (NASDAQ: [[ticker:IMMU]]) has appointed Loretta Itri to serve as chief medical officer. Itri was most recently executive vice president of global health sciences & regulatory affairs at The Medicines Company. Her experience also includes roles at Genta, Johnson & Johnson (NYSE: [[ticker:JNJ]]), Ortho Biotech, and Roche. Morris Plains, NJ-based Immunomedics is awaiting an FDA decision on its lead drug, sacituzumab govitecan, which was developed to treat triple-negative breast cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan